Open Access Articles- Top Results for Adefovir


Systematic (IUPAC) name
{[2-(6-amino-9H-purin-9-yl)ethoxy]methyl}phosphonic acid
Clinical data
Trade names Hepsera
AHFS/ monograph
  • AU: B3
  • US: C (Risk not ruled out)
Pharmacokinetic data
Bioavailability 59%
Protein binding <4%
Half-life 7.5 hours
Excretion Urine
106941-25-7 7pxN
PubChem CID 60172
DrugBank DB00718 7pxY
ChemSpider 54252 7pxY
UNII 6GQP90I798 7pxY
KEGG D02768 7pxY
NIAID ChemDB 028595
Chemical data
Formula C8H12N5O4P
273.186 g/mol
 14pxN (what is this?)  (verify)

Adefovir is a prescription medicine used to treat (chronic) infections with hepatitis B virus. A prodrug form of Adefovir was previously called bis-POM PMEA, with trade names Preveon and Hepsera. It is an orally administered nucleotide analog reverse transcriptase inhibitor (ntRTI). It can be formulated as the pivoxil prodrug adefovir dipivoxil.


It is used for treatment of hepatitis B [1][2] and herpes simplex virus infection. [3]

It is a failed treatment for HIV.[3][4]


Adefovir was invented in the Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic by Antonín Holý, and the drug was developed by Gilead Sciences for HIV with the brand name Preveon. However, in November 1999, an expert panel advised the U.S. Food and Drug Administration (FDA) not to approve the drug due to concerns about the severity and frequency of kidney toxicity when dosed at 60 or 120 mg. The FDA followed that advice, refusing to approve adefovir as a treatment for HIV.

Gilead Sciences discontinued its development for HIV treatment in December 1999, but continued to develop the drug for hepatitis B (HBV), where it is effective with a much lower dose of 10 mg. FDA approval for use in the treatment of hepatitis B was granted on September 20, 2002, and adefovir is sold for this indication under the brand name Hepsera. Adefovir became an approved treatment for HBV in the European Union in March 2003.

Mechanism of action

Adefovir works by blocking reverse transcriptase, an enzyme crucial for the HBV to reproduce in the body. It is approved for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (primarily ALT) or histologically active disease.

The main benefit of adefovir over lamivudine (the first NRTI approved for the treatment of HBV) is that it takes a much longer period of time for the virus to develop resistance to it.

Adefovir dipivoxil contains two pivaloyloxymethyl units, making it a prodrug form of adefovir.


  1. ^ Marcellin P; Chang TT; Lim SG et al. (February 2003). "Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B". N. Engl. J. Med. 348 (9): 808–16. PMID 12606735. doi:10.1056/NEJMoa020681. 
  2. ^ Manolakopoulos S; Bethanis S; Koutsounas S et al. (February 2008). "Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine". Aliment. Pharmacol. Ther. 27 (3): 266–73. PMID 17988233. doi:10.1111/j.1365-2036.2007.03567.x. 
  3. ^ a b ADHOC International Steering Committee (October 2002). "A randomized placebo-controlled trial of adefovir dipivoxil in advanced HIV infection: the ADHOC trial". HIV Med. 3 (4): 229–38. PMID 12444940. doi:10.1046/j.1468-1293.2002.00111.x. 
  4. ^ Fisher EJ; Chaloner K; Cohn DL et al. (September 2001). "The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial". AIDS 15 (13): 1695–700. PMID 11546945. doi:10.1097/00002030-200109070-00013. 

External links